Advertisement

Journal of Neuro-Oncology

, Volume 116, Issue 1, pp 77–82 | Cite as

Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma

  • Ming Zhou
  • Kangwu Chen
  • Huilin YangEmail author
  • Genlin Wang
  • Jian Lu
  • Yiming Ji
  • Chunshen Wu
  • Chao Chen
Laboratory Investigation

Abstract

Sacral chordoma is a rare and aggressive tumor, with a high rate of local recurrence even when the tumor is radically resected. The fundamental knowledge of its biological behavior remains unknown. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is one of the RNA binding proteins and is expressed during embryogenesis and in various malignant tumors. This study evaluated expression of IMP3 in sacral chordoma for association with patient’s clinicopathological factors. A total of 32 patients with sacral chordoma (17 male and 15 female) and 10 samples of distant normal tissues were collected for analysis of IMP3 expression using immunohistochemistry. Association between IMP3 expression and clinicopathological factors (such as patient’s age, gender, tumor location, tumor size, surrounding muscle invasion, Ki-67 expression, and tumor recurrence) were statistically analyzed. IMP3 was expressed in 20 (62.5 %) patients, whereas there was no expression in the 10 distant normal tissues. IMP3 expression was associated with tumor invasion into the surrounding muscle (P = 0.028), high levels of Ki-67 expression (P = 0.009), and tumor recurrence (P = 0.012). The log-rank test revealed that patients with positive IMP3 expression had a shorter continuous disease-free survival time than those with negative IMP3 expression (P = 0.016). IMP3 expression was independent of age, gender, tumor location and tumor size. These results indicate that IMP3 was overexpressed in sacral chordoma and this expression was associated with tumor invasion and recurrence; thus, IMP3 may play an important role in tumor progression and could serve as a prognostic biomarker for sacral chordoma and IMP3 could be used as a potential therapeutic target for the treatment of sacral chordoma.

Keywords

Chordoma Sacral Immunohistochemistry IMP3 Tumor recurrence Survival 

Notes

Acknowledgments

We would like to thank Gu Yongping for technical guidance during the immunohistochemical analysis.

Conflict of interest

There are no conflicts of interest to be declared for this work.

References

  1. 1.
    McMaster ML, Goldstein AM, Bromley CM, Ishibe N, Parry DM (2001) Chordoma: incidence and survival patterns in the United States. Cancer Causes Control 12:1973–1995CrossRefGoogle Scholar
  2. 2.
    Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, Baker LH (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12:1344–1350PubMedCrossRefGoogle Scholar
  3. 3.
    Sciubba DM, Cheng JJ, Petteys RJ, Weber KL, Frassica DA, Gokaslan ZL (2009) Chordoma of the sacrum and vertebral bodies. J Am Acad Orthop Surg 17:708–717PubMedGoogle Scholar
  4. 4.
    York JE, Kaczaraj A, Abi-Said D, Fuller GN, Skibber JM, Janjan NA, Gokaslan ZL (1999) Sacral chordoma: 40-year experience at a major cancer center. Neurosurgery 44:74–79PubMedCrossRefGoogle Scholar
  5. 5.
    Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P (2010) Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211–219PubMedCrossRefGoogle Scholar
  6. 6.
    Pamir MN, Ozduman K (2008) Tumor-biology and current treatment of skull-base chordomas. Adv Tech Stand Neurosurg 33:35–129PubMedCrossRefGoogle Scholar
  7. 7.
    Nielsen J, Christiansen J, Lykke-Andersen J, Johnsen AH, Wewer UM, Nielsen FC (1999) A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 19:1262–1270PubMedCentralPubMedGoogle Scholar
  8. 8.
    Mueller-Pillasch F, Pohl B, Wilda M, Lacher U, Beil M, Wallrapp C, Hameister H, Knochel W, Adler G, Gress TM (1999) Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88:95–99PubMedCrossRefGoogle Scholar
  9. 9.
    Wang T, Fan L, Watanabe Y, McNeill PD, Moulton GG, Bangur C, Fanger G, Okada M, Inoue Y, Persing D, Reed SG (2003) L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88:887–894PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Yantiss RK, Woda BA, Fanger GR, Kalos M, Whalen GF, Tada H, Andersen DK, Rock KL, Dresser K (2005) KOC (K homology domain containing protein overexpressed in cancer)—a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29:188–195PubMedCrossRefGoogle Scholar
  11. 11.
    Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM (1997) Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14:2729–2733PubMedCrossRefGoogle Scholar
  12. 12.
    Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q, Hsieh CC, Li C, Chen W, Duan HO, McDougal S, Wu CL (2006) Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7:556–564PubMedCrossRefGoogle Scholar
  13. 13.
    Sitnikova L, Mendese G, Liu Q, Woda BA, Lu D, Dresser K, Mohanty S, Rock KL, Jiang Z (2008) IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res 14:1701–1706PubMedCrossRefGoogle Scholar
  14. 14.
    Li DW, Yan DW, Tang HM, Zhou CZ, Fan JW, Li SX, Wang XL, Xia J, Huang F, Qiu GQ, Peng ZH (2009) IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis. Ann Surg Oncol 16:3499–3506PubMedCrossRefGoogle Scholar
  15. 15.
    Do SI, Kim YW, Park HR, Park YK (2008) Expression of insulin-like growth factor-II mRNA binding protein 3 (IMP3) in osteosarcoma. Oncol Res 17:269–272PubMedCrossRefGoogle Scholar
  16. 16.
    Hanna SA, Aston WJS, Briggs TWR, Cannon SR, Saifuddin A (2008) Sacral chordoma: can local recurrence after sacrectomy be predicted? Clin Orthop Relat Res 466:2217–2223PubMedCrossRefGoogle Scholar
  17. 17.
    Chen KW, Yang HL, Lu J, Liu JY, Chen XQ (2010) Prognostic factors of sacral chordoma after surgical therapy: a study of 36 patients. Spinal Cord 48:166–171PubMedCrossRefGoogle Scholar
  18. 18.
    Chen KW, Yang HL, Lu J, Wang GL, Ji YM, Wu GZ, Zhu LF, Liu JY, Chen XQ, Gu YP (2011) Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. J Neurooncol 101:357–363PubMedCrossRefGoogle Scholar
  19. 19.
    Yang HL, Zhu LF, Ebraheim NA, Liu XC, Castillo S, Tang TS, Liu JY, Cui HJ (2009) Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Spine J 9:972–980PubMedCrossRefGoogle Scholar
  20. 20.
    Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, Gronchi A, Picci P (2010) Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol 17:211–219PubMedCrossRefGoogle Scholar
  21. 21.
    Findeis-Hosey JJ, Xu HD (2011) The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 42:303–314PubMedCrossRefGoogle Scholar
  22. 22.
    Vikesaa J, Hansen TV, Jonson L, Borup R, Wewer UM, Christiansen J, Nielsen FC (2006) RNA-binding IMPs promote cell adhesion and invadopodia formation. EMBO J 25:1456–1468PubMedCrossRefGoogle Scholar
  23. 23.
    Samanta S, Sharma VM, Khan A, Mercurio AM (2012) Regulation of IMP3 by EGFR signaling and repression by ERbeta: implications for triple-negative breast cancer. Oncogene 31:4689–4697PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Liao B, Hu Y, Herrick DJ, Brewer G (2005) The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 280:18517–18524PubMedCrossRefGoogle Scholar
  25. 25.
    Mori H, Sakakibara S, Imai T, Nakamura Y, Iijima T, Suzuki A, Yuasa Y, Takeda M, Okano H (2001) Expression of mouse igf2 mRNA-binding protein 3 and its implications for the developing central nervous system. J Neurosci Res 64:132–143PubMedCrossRefGoogle Scholar
  26. 26.
    Chen KW, Yang HL, Kandimalla Y, Liu JY, Wang GL (2009) Review of current treatment of sacral chordoma. Orthop Surg 1:238–244PubMedCrossRefGoogle Scholar
  27. 27.
    Lochhead P, Imamura Y, Morikawa T, Kuchiba A, Yamauchi M, Liao XY, Qian ZR, Nishihara R, Wu K, Meyerhardt JA, Fuchs CS, Ogino S (2012) Insulin-like growth factor 2 messenger RNA binding protein 3 (IGF2BP3) is a marker of unfavourable prognosis in colorectal cancer. Eur J Cancer 48:3405–3413PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Chen YL, Jeng YM, Hsu HC, Lai HS, Lee PH, Lai PL, Yuan RH (2013) Expression of insulin-like growth factor II mRNA-binding protein 3 predicts early recurrence and poor prognosis in intrahepatic cholangiocarcinoma. Int J Surg 11:85–91PubMedCrossRefGoogle Scholar
  29. 29.
    Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H (2007) Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci 98:1803–1808CrossRefGoogle Scholar
  30. 30.
    Kono K, Mizukami Y, Daigo Y, Takano A, Masuda K, Yoshida K, Tsunoda T, Kawaguchi Y, Nakamura Y, Fujii H (2009) Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 100:1502–1509PubMedCrossRefGoogle Scholar
  31. 31.
    Kono K, Iinuma H, Akutsu Y, Tanaka H, Hayashi N, Uchikado Y, Noguchi T, Fujii H, Okinaka K, Fukushima R, Matsubara H, Ohira M, Baba H, Natsugoe S, Kitano S, Takeda K, Yoshida K, Tsunoda T, Nakamura Y (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. J Transl Med 10:141PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ming Zhou
    • 1
    • 2
  • Kangwu Chen
    • 1
  • Huilin Yang
    • 1
    Email author
  • Genlin Wang
    • 1
  • Jian Lu
    • 1
  • Yiming Ji
    • 1
  • Chunshen Wu
    • 1
  • Chao Chen
    • 1
  1. 1.Department of Orthopedic SurgeryThe First Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of Orthopedic SurgeryWuxi Ninth People’s Hospital Affiliated to Soochow UniversityWuxiChina

Personalised recommendations